Table of Content

1 Market Overview of Gene Therapy for Neurodegenerative Diseases
1.1 Gene Therapy for Neurodegenerative Diseases Market Overview
1.1.1 Gene Therapy for Neurodegenerative Diseases Product Scope
1.1.2 Gene Therapy for Neurodegenerative Diseases Market Status and Outlook
1.2 Global Gene Therapy for Neurodegenerative Diseases Market Size Overview by Region 2018 VS 2022 VS 2033
1.3 Global Gene Therapy for Neurodegenerative Diseases Market Size by Region (2018-2033)
1.4 Global Gene Therapy for Neurodegenerative Diseases Historic Market Size by Region (2018-2023)
1.5 Global Gene Therapy for Neurodegenerative Diseases Market Size Forecast by Region (2024-2033)
1.6 Key Regions, Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033)
1.6.1 North America Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033)
1.6.2 Europe Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033)
1.6.3 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033)
1.6.4 Latin America Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033)
1.6.5 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033)
2 Gene Therapy for Neurodegenerative Diseases Market by Type
2.1 Introduction
2.1.1 Gene Replacement Therapy
2.1.2 Gene Silencing Therapy
2.1.3 Gene Editing Therapy
2.1.4 Enzyme Replacement Therapy
2.2 Global Gene Therapy for Neurodegenerative Diseases Market Size by Type: 2018 VS 2022 VS 2033
2.2.1 Global Gene Therapy for Neurodegenerative Diseases Historic Market Size by Type (2018-2023)
2.2.2 Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Type (2024-2033)
2.3 Key Regions Market Size by Type
2.3.1 North America Gene Therapy for Neurodegenerative Diseases Revenue Breakdown by Type (2018-2033)
2.3.2 Europe Gene Therapy for Neurodegenerative Diseases Revenue Breakdown by Type (2018-2033)
2.3.3 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Revenue Breakdown by Type (2018-2033)
2.3.4 Latin America Gene Therapy for Neurodegenerative Diseases Revenue Breakdown by Type (2018-2033)
2.3.5 Middle East and Africa Gene Therapy for Neurodegenerative Diseases Revenue Breakdown by Type (2018-2033)
3 Gene Therapy for Neurodegenerative Diseases Market Overview by Application
3.1 Introduction
3.1.1 Hospitals and Clinics
3.1.2 Research Institutions
3.1.3 Biotechnology Companies
3.1.4 Others
3.2 Global Gene Therapy for Neurodegenerative Diseases Market Size by Application: 2018 VS 2022 VS 2033
3.2.1 Global Gene Therapy for Neurodegenerative Diseases Historic Market Size by Application (2018-2023)
3.2.2 Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Application (2024-2033)
3.3 Key Regions Market Size by Application
3.3.1 North America Gene Therapy for Neurodegenerative Diseases Revenue Breakdown by Application (2018-2033)
3.3.2 Europe Gene Therapy for Neurodegenerative Diseases Revenue Breakdown by Application (2018-2033)
3.3.3 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Revenue Breakdown by Application (2018-2033)
3.3.4 Latin America Gene Therapy for Neurodegenerative Diseases Revenue Breakdown by Application (2018-2033)
3.3.5 Middle East and Africa Gene Therapy for Neurodegenerative Diseases Revenue Breakdown by Application (2018-2033)
4 Gene Therapy for Neurodegenerative Diseases Competition Analysis by Players
4.1 Global Gene Therapy for Neurodegenerative Diseases Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Gene Therapy for Neurodegenerative Diseases as of 2022)
4.3 Date of Key Players Enter into Gene Therapy for Neurodegenerative Diseases Market
4.4 Global Top Players Gene Therapy for Neurodegenerative Diseases Headquarters and Area Served
4.5 Key Players Gene Therapy for Neurodegenerative Diseases Product Solution and Service
4.6 Competitive Status
4.6.1 Gene Therapy for Neurodegenerative Diseases Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Voyager Therapeutics
5.1.1 Voyager Therapeutics Profile
5.1.2 Voyager Therapeutics Main Business
5.1.3 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Products, Services and Solutions
5.1.4 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue (US$ Million) & (2018-2023)
5.1.5 Voyager Therapeutics Recent Developments
5.2 Uniqure N.V.
5.2.1 Uniqure N.V. Profile
5.2.2 Uniqure N.V. Main Business
5.2.3 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Products, Services and Solutions
5.2.4 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Revenue (US$ Million) & (2018-2023)
5.2.5 Uniqure N.V. Recent Developments
5.3 Axovant Gene Therapies
5.3.1 Axovant Gene Therapies Profile
5.3.2 Axovant Gene Therapies Main Business
5.3.3 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Products, Services and Solutions
5.3.4 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Revenue (US$ Million) & (2018-2023)
5.3.5 Novartis Ag Recent Developments
5.4 Novartis Ag
5.4.1 Novartis Ag Profile
5.4.2 Novartis Ag Main Business
5.4.3 Novartis Ag Gene Therapy for Neurodegenerative Diseases Products, Services and Solutions
5.4.4 Novartis Ag Gene Therapy for Neurodegenerative Diseases Revenue (US$ Million) & (2018-2023)
5.4.5 Novartis Ag Recent Developments
5.5 Amicus Therapeutics
5.5.1 Amicus Therapeutics Profile
5.5.2 Amicus Therapeutics Main Business
5.5.3 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Products, Services and Solutions
5.5.4 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue (US$ Million) & (2018-2023)
5.5.5 Amicus Therapeutics Recent Developments
5.6 Regenxbio Inc.
5.6.1 Regenxbio Inc. Profile
5.6.2 Regenxbio Inc. Main Business
5.6.3 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Products, Services and Solutions
5.6.4 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Revenue (US$ Million) & (2018-2023)
5.6.5 Regenxbio Inc. Recent Developments
5.7 Sarepta Therapeutics
5.7.1 Sarepta Therapeutics Profile
5.7.2 Sarepta Therapeutics Main Business
5.7.3 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Products, Services and Solutions
5.7.4 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue (US$ Million) & (2018-2023)
5.7.5 Sarepta Therapeutics Recent Developments
5.8 Gensight Biologics
5.8.1 Gensight Biologics Profile
5.8.2 Gensight Biologics Main Business
5.8.3 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Products, Services and Solutions
5.8.4 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Revenue (US$ Million) & (2018-2023)
5.8.5 Gensight Biologics Recent Developments
5.9 Krystal Biotech
5.9.1 Krystal Biotech Profile
5.9.2 Krystal Biotech Main Business
5.9.3 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Products, Services and Solutions
5.9.4 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Revenue (US$ Million) & (2018-2023)
5.9.5 Krystal Biotech Recent Developments
5.10 Avexis
5.10.1 Avexis Profile
5.10.2 Avexis Main Business
5.10.3 Avexis Gene Therapy for Neurodegenerative Diseases Products, Services and Solutions
5.10.4 Avexis Gene Therapy for Neurodegenerative Diseases Revenue (US$ Million) & (2018-2023)
5.10.5 Avexis Recent Developments
6 North America
6.1 North America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2033)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2033)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size by Region (2018-2033)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2033)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2033)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Gene Therapy for Neurodegenerative Diseases Market Dynamics
11.1 Gene Therapy for Neurodegenerative Diseases Industry Trends
11.2 Gene Therapy for Neurodegenerative Diseases Market Drivers
11.3 Gene Therapy for Neurodegenerative Diseases Market Challenges
11.4 Gene Therapy for Neurodegenerative Diseases Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Gene Therapy for Neurodegenerative Diseases Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2033
Table 2. Global Gene Therapy for Neurodegenerative Diseases Market Size by Region (2018-2023) & (US$ Million)
Table 3. Global Gene Therapy for Neurodegenerative Diseases Market Size Share by Region (2018-2023)
Table 4. Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 5. Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size Share by Region (2024-2033)
Table 6. Global Gene Therapy for Neurodegenerative Diseases Market Size (US$ Million) by Type: 2018 VS 2022 VS 2033
Table 7. Global Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & (US$ Million)
Table 8. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Type (2018-2023)
Table 9. Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 10. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Type (2024-2033)
Table 11. North America Gene Therapy for Neurodegenerative Diseases Revenue by Type (2018-2023) & (US$ Million)
Table 12. North America Gene Therapy for Neurodegenerative Diseases Revenue by Type (2024-2033) & (US$ Million)
Table 13. Europe Gene Therapy for Neurodegenerative Diseases Revenue by Type (2018-2023) & (US$ Million)
Table 14. Europe Gene Therapy for Neurodegenerative Diseases Revenue by Type (2024-2033) & (US$ Million)
Table 15. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Revenue by Type (2018-2023) & (US$ Million)
Table 16. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Revenue by Type (2024-2033) & (US$ Million)
Table 17. Latin America Gene Therapy for Neurodegenerative Diseases Revenue by Type (2018-2023) & (US$ Million)
Table 18. Latin America Gene Therapy for Neurodegenerative Diseases Revenue by Type (2024-2033) & (US$ Million)
Table 19. Middle East and Africa Gene Therapy for Neurodegenerative Diseases Revenue by Type (2018-2023) & (US$ Million)
Table 20. Middle East and Africa Gene Therapy for Neurodegenerative Diseases Revenue by Type (2024-2033) & (US$ Million)
Table 21. Global Gene Therapy for Neurodegenerative Diseases Market Size (US$ Million) by Application: 2018 VS 2022 VS 2033
Table 22. Global Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & (US$ Million)
Table 23. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Application (2018-2023)
Table 24. Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 25. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Application (2024-2033)
Table 26. North America Gene Therapy for Neurodegenerative Diseases Revenue by Application (2018-2023) & (US$ Million)
Table 27. North America Gene Therapy for Neurodegenerative Diseases Revenue by Application (2024-2033) & (US$ Million)
Table 28. Europe Gene Therapy for Neurodegenerative Diseases Revenue by Application (2018-2023) & (US$ Million)
Table 29. Europe Gene Therapy for Neurodegenerative Diseases Revenue by Application (2024-2033) & (US$ Million)
Table 30. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Revenue by Application (2018-2023) & (US$ Million)
Table 31. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Revenue by Application (2024-2033) & (US$ Million)
Table 32. Latin America Gene Therapy for Neurodegenerative Diseases Revenue by Application (2018-2023) & (US$ Million)
Table 33. Latin America Gene Therapy for Neurodegenerative Diseases Revenue by Application (2024-2033) & (US$ Million)
Table 34. Middle East and Africa Gene Therapy for Neurodegenerative Diseases Revenue by Application (2018-2023) & (US$ Million)
Table 35. Middle East and Africa Gene Therapy for Neurodegenerative Diseases Revenue by Application (2024-2033) & (US$ Million)
Table 36. Global Gene Therapy for Neurodegenerative Diseases Revenue (US$ Million) by Players (2018-2023)
Table 37. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Players (2018-2023)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Gene Therapy for Neurodegenerative Diseases as of 2022)
Table 39. Date of Key Players Enter into Gene Therapy for Neurodegenerative Diseases Market
Table 40. Global Gene Therapy for Neurodegenerative Diseases Key Players Headquarters and Area Served
Table 41. Gene Therapy for Neurodegenerative Diseases Product Solution and Service
Table 42. Global Gene Therapy for Neurodegenerative Diseases Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. Voyager Therapeutics Basic Information List
Table 45. Voyager Therapeutics Description and Business Overview
Table 46. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Products, Services and Solutions
Table 47. Revenue (US$ Million) in Gene Therapy for Neurodegenerative Diseases Business of Voyager Therapeutics (2018-2023)
Table 48. Voyager Therapeutics Recent Developments
Table 49. Uniqure N.V. Basic Information List
Table 50. Uniqure N.V. Description and Business Overview
Table 51. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Products, Services and Solutions
Table 52. Revenue (US$ Million) in Gene Therapy for Neurodegenerative Diseases Business of Uniqure N.V. (2018-2023)
Table 53. Uniqure N.V. Recent Developments
Table 54. Axovant Gene Therapies Basic Information List
Table 55. Axovant Gene Therapies Description and Business Overview
Table 56. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Products, Services and Solutions
Table 57. Revenue (US$ Million) in Gene Therapy for Neurodegenerative Diseases Business of Axovant Gene Therapies (2018-2023)
Table 58. Axovant Gene Therapies Recent Developments
Table 59. Novartis Ag Basic Information List
Table 60. Novartis Ag Description and Business Overview
Table 61. Novartis Ag Gene Therapy for Neurodegenerative Diseases Products, Services and Solutions
Table 62. Revenue (US$ Million) in Gene Therapy for Neurodegenerative Diseases Business of Novartis Ag (2018-2023)
Table 63. Novartis Ag Recent Developments
Table 64. Amicus Therapeutics Basic Information List
Table 65. Amicus Therapeutics Description and Business Overview
Table 66. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Products, Services and Solutions
Table 67. Revenue (US$ Million) in Gene Therapy for Neurodegenerative Diseases Business of Amicus Therapeutics (2018-2023)
Table 68. Amicus Therapeutics Recent Developments
Table 69. Regenxbio Inc. Basic Information List
Table 70. Regenxbio Inc. Description and Business Overview
Table 71. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Products, Services and Solutions
Table 72. Revenue (US$ Million) in Gene Therapy for Neurodegenerative Diseases Business of Regenxbio Inc. (2018-2023)
Table 73. Regenxbio Inc. Recent Developments
Table 74. Sarepta Therapeutics Basic Information List
Table 75. Sarepta Therapeutics Description and Business Overview
Table 76. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Products, Services and Solutions
Table 77. Revenue (US$ Million) in Gene Therapy for Neurodegenerative Diseases Business of Sarepta Therapeutics (2018-2023)
Table 78. Sarepta Therapeutics Recent Developments
Table 79. Gensight Biologics Basic Information List
Table 80. Gensight Biologics Description and Business Overview
Table 81. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Products, Services and Solutions
Table 82. Revenue (US$ Million) in Gene Therapy for Neurodegenerative Diseases Business of Gensight Biologics (2018-2023)
Table 83. Gensight Biologics Recent Developments
Table 84. Krystal Biotech Basic Information List
Table 85. Krystal Biotech Description and Business Overview
Table 86. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Products, Services and Solutions
Table 87. Revenue (US$ Million) in Gene Therapy for Neurodegenerative Diseases Business of Krystal Biotech (2018-2023)
Table 88. Krystal Biotech Recent Developments
Table 89. Avexis Basic Information List
Table 90. Avexis Description and Business Overview
Table 91. Avexis Gene Therapy for Neurodegenerative Diseases Products, Services and Solutions
Table 92. Revenue (US$ Million) in Gene Therapy for Neurodegenerative Diseases Business of Avexis (2018-2023)
Table 93. Avexis Recent Developments
Table 94. North America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023) & (US$ Million)
Table 95. North America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2033) & (US$ Million)
Table 96. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023) & (US$ Million)
Table 97. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2033) & (US$ Million)
Table 98. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 99. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size by Region (2018-2023) & (US$ Million)
Table 100. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size by Region (2024-2033) & (US$ Million)
Table 101. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Share by Region (2018-2023)
Table 102. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Share by Region (2024-2033)
Table 103. Latin America Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 104. Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023) & (US$ Million)
Table 105. Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2033) & (US$ Million)
Table 106. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 107. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023) & (US$ Million)
Table 108. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2033) & (US$ Million)
Table 109. Gene Therapy for Neurodegenerative Diseases Market Trends
Table 110. Gene Therapy for Neurodegenerative Diseases Market Drivers
Table 111. Gene Therapy for Neurodegenerative Diseases Market Challenges
Table 112. Gene Therapy for Neurodegenerative Diseases Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Gene Therapy for Neurodegenerative Diseases Market Size Year-over-Year 2018-2033 & (US$ Million)
Figure 2. Global Gene Therapy for Neurodegenerative Diseases Market Size (US$ Million), 2018 VS 2022 VS 2033
Figure 3. Global Gene Therapy for Neurodegenerative Diseases Market Share by Regions: 2022 VS 2033
Figure 4. Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size Share by Region (2024-2033)
Figure 5. North America Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 6. Europe Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 7. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 8. Latin America Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 9. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 10. Product Picture of Gene Replacement Therapy
Figure 11. Global Gene Replacement Therapy Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 12. Product Picture of Gene Silencing Therapy
Figure 13. Global Gene Silencing Therapy Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 14. Product Picture of Gene Editing Therapy
Figure 15. Global Gene Editing Therapy Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 16. Product Picture of Enzyme Replacement Therapy
Figure 17. Global Enzyme Replacement Therapy Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 18. Global Gene Therapy for Neurodegenerative Diseases Market Size Share by Type: 2022 & 2033
Figure 19. North America Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Type (2018-2033)
Figure 20. Europe Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Type (2018-2033)
Figure 21. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Type (2018-2033)
Figure 22. Latin America Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Type (2018-2033)
Figure 23. Middle East and Africa Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Type (2018-2033)
Figure 24. Hospitals and Clinics Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 25. Research Institutions Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 26. Biotechnology Companies Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 27. Others Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 28. Global Gene Therapy for Neurodegenerative Diseases Market Size Share by Application: 2022 & 2033
Figure 29. North America Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Application (2018-2033)
Figure 30. Europe Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Application (2018-2033)
Figure 31. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Application (2018-2033)
Figure 32. Latin America Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Application (2018-2033)
Figure 33. Middle East and Africa Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Application (2018-2033)
Figure 34. Gene Therapy for Neurodegenerative Diseases Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 35. Global Top 5 and Top 10 Players Gene Therapy for Neurodegenerative Diseases Market Share in 2022
Figure 36. North America Gene Therapy for Neurodegenerative Diseases Market Share by Country (2018-2033)
Figure 37. United States Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033) & (US$ Million)
Figure 38. Canada Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033) & (US$ Million)
Figure 39. Germany Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033) & (US$ Million)
Figure 40. France Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033) & (US$ Million)
Figure 41. U.K. Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033) & (US$ Million)
Figure 42. Italy Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033) & (US$ Million)
Figure 43. Russia Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033) & (US$ Million)
Figure 44. Nordic Countries Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033) & (US$ Million)
Figure 45. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Share by Region (2018-2033)
Figure 46. China Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033) & (US$ Million)
Figure 47. Japan Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033) & (US$ Million)
Figure 48. South Korea Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033) & (US$ Million)
Figure 49. Southeast Asia Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033) & (US$ Million)
Figure 50. India Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033) & (US$ Million)
Figure 51. Australia Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033) & (US$ Million)
Figure 52. Latin America Gene Therapy for Neurodegenerative Diseases Market Share by Country (2018-2033)
Figure 53. Mexico Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033) & (US$ Million)
Figure 54. Brazil Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033) & (US$ Million)
Figure 55. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Share by Country (2018-2033)
Figure 56. Turkey Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033) & (US$ Million)
Figure 57. Saudi Arabia Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033) & (US$ Million)
Figure 58. UAE Gene Therapy for Neurodegenerative Diseases Market Size (2018-2033) & (US$ Million)
Figure 59. Bottom-up and Top-down Approaches for This Report